DLBCL in 2023: Top Docs Discuss the LATEST in Diffuse Large B-Cell Lymphoma | Treatments & Research
14.5 هزار بار بازدید -
2 سال پیش
-
The Patient Story founder Stephanie
The Patient Story founder Stephanie Chuang was diagnosed with Diffuse Large B-Cell Lymphoma at 31. Like many others, she was completely overwhelmed. After undergoing treatment she was able to reach remission. But throughout her cancer journey, she felt a great need for more options in treatment. She wanted to know, what are the treatments out there? What are the options? What should you be asking your doctor?
In this conversation, she speaks with Dr. Josh Brody, who leads the Lymphoma Immunotherapy Program at Mount Sinai and Dr. Lorenzo Falchi, an oncologist at Memorial Sloan Kettering Cancer Center with special research focus on immunotherapies for B-cell non-Hodgkin lymphoma. They discuss breakthrough therapies for DLBCL, immunotherapy and bispecific antibodies.
Special thanks to Genmab for its support of our patient education program!
Full story & transcript → https://www.thepatientstory.com/medic...
Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
Contents of this Video:
00:00 - Intro
03:19 - "Why me?" How did I get Diffuse Large B-Cell Lymphoma (DLBCL)?
07:17 - CAR T-cell therapy may become an earlier option?
08:38 - What are bispecific antibodies?
11:30 - Which bispecific antibodies in clinical trials are emerging as likeliest to get approvals sooner?
14:07 - What are the most common side effects seen with bispecifics so far?
19:58 - Different ways bispecifics could be used in treatment
24:39 - Importance of "Patient Reported Outcomes"
26:37 - What is the general takeaway for DLBCL patients and loved ones today?
#cancersurvivor #cancerstories #cancer #thepatientstory #dlbcl #lymsm #nonhodgkinlymphoma #lymphoma #lymphomasurvivor #lymphomaawareness #cancertreatments #cancerresearch
In this conversation, she speaks with Dr. Josh Brody, who leads the Lymphoma Immunotherapy Program at Mount Sinai and Dr. Lorenzo Falchi, an oncologist at Memorial Sloan Kettering Cancer Center with special research focus on immunotherapies for B-cell non-Hodgkin lymphoma. They discuss breakthrough therapies for DLBCL, immunotherapy and bispecific antibodies.
Special thanks to Genmab for its support of our patient education program!
Full story & transcript → https://www.thepatientstory.com/medic...
Join Our Community:
Website : https://www.thepatientstory.com/
Facebook: @ThePatientStory
Instagram: @ThePatientStory
Twitter: @patient_story
Contents of this Video:
00:00 - Intro
03:19 - "Why me?" How did I get Diffuse Large B-Cell Lymphoma (DLBCL)?
07:17 - CAR T-cell therapy may become an earlier option?
08:38 - What are bispecific antibodies?
11:30 - Which bispecific antibodies in clinical trials are emerging as likeliest to get approvals sooner?
14:07 - What are the most common side effects seen with bispecifics so far?
19:58 - Different ways bispecifics could be used in treatment
24:39 - Importance of "Patient Reported Outcomes"
26:37 - What is the general takeaway for DLBCL patients and loved ones today?
#cancersurvivor #cancerstories #cancer #thepatientstory #dlbcl #lymsm #nonhodgkinlymphoma #lymphoma #lymphomasurvivor #lymphomaawareness #cancertreatments #cancerresearch
2 سال پیش
در تاریخ 1401/10/21 منتشر شده
است.
14,579
بـار بازدید شده